Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
